Opinion|Videos|November 1, 2024
Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification
Key Takeaways
- mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably.
- Both conditions involve the presence of metastases and sensitivity to androgen deprivation therapy (ADT).
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.
Advertisement
Video content above is prompted by the following:
How do you define mCSPC and mHSPC? How are they different? (
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Annual ACS NCDB report details national trends in prostate cancer care
2
Treatment Selection in Advanced Prostate Cancer
3
Docetaxel plus tumor-targeting IL-12 yields promising activity in mCRPC
4
FDA provides guidance on development pathway for testosterone therapy for women
5